PMID- 32444802
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20210522
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 May 22
TI  - Identification of prognostic signature of non-small cell lung cancer based on 
      TCGA methylation data.
PG  - 8575
LID - 10.1038/s41598-020-65479-y [doi]
LID - 8575
AB  - Non-small lung cancer (NSCLC) is a common malignant disease with very poor 
      outcome. Accurate prediction of prognosis can better guide patient risk 
      stratification and treatment decision making, and could optimize the outcome. 
      Utilizing clinical and methylation/expression data in The Cancer Genome Atlas 
      (TCGA), we conducted comprehensive evaluation of early-stage NSCLC to identify a 
      methylation signature for survival prediction. 349 qualified cases of NSCLC with 
      curative surgery were included and further grouped into the training and 
      validation cohorts. We identified 4000 methylation loci with prognostic influence 
      on univariate and multivariate regression analysis in the training cohort. KEGG 
      pathway analysis was conducted to identify the key pathway. Hierarchical 
      clustering and WGCNA co-expression analysis was performed to classify the sample 
      phenotype and molecular subtypes. Hub 5'-C-phosphate-G-3' (CpG) loci were 
      identified by network analysis and then further applied for the construction of 
      the prognostic signature. The predictive power of the prognostic model was 
      further validated in the validation cohort. Based on clustering analysis, we 
      identified 6 clinical molecular subtypes, which were associated with different 
      clinical characteristics and overall survival; clusters 4 and 6 demonstrated the 
      best and worst outcomes. We identified 17 hub CpG loci, and their weighted 
      combination was used for the establishment of a prognostic model (RiskScore). The 
      RiskScore significantly correlated with post-surgical outcome; patients with a 
      higher RiskScore have worse overall survival in both the training and validation 
      cohorts (P < 0.01). We developed a novel methylation signature that can reliably 
      predict prognosis for patients with NSCLC.
FAU - Wang, Yifan
AU  - Wang Y
AD  - Institute of Cancer and Basic medicine (ICBM), Chinese Academy of Sciences, 
      Zhejiang, China.
AD  - Ultrasonic Department, Cancer Hospital of the University of Chinese Academy of 
      Sciences, Zhejiang, China.
AD  - Ultrasonic Department, Zhejiang Cancer Hospital, Zhejiang, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Basic Medical Science, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Institute of Cancer and Basic medicine (ICBM), Chinese Academy of Sciences, 
      Zhejiang, China.
AD  - Department of Gynecological Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences, Zhejiang, China.
AD  - Department of Gynecological Oncology, Zhejiang Cancer Hospital, Zhejiang, China.
FAU - Zhang, Yongjun
AU  - Zhang Y
AD  - Institute of Cancer and Basic medicine (ICBM), Chinese Academy of Sciences, 
      Zhejiang, China. zhangyj@zjcc.org.cn.
AD  - Department of Integration of Traditional Chinese and Western Medicine, Cancer 
      Hospital of the University of Chinese Academy of Sciences, Zhejiang, China. 
      zhangyj@zjcc.org.cn.
AD  - Department of Integration of Traditional Chinese and Western Medicine, Zhejiang 
      Cancer Hospital, Zhejiang, China. zhangyj@zjcc.org.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200522
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*pathology
MH  - Cohort Studies
MH  - CpG Islands
MH  - *DNA Methylation
MH  - *Databases, Genetic
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Survival Rate
PMC - PMC7244759
COIS- The authors declare no competing interests.
EDAT- 2020/05/24 06:00
MHDA- 2020/12/02 06:00
PMCR- 2020/05/22
CRDT- 2020/05/24 06:00
PHST- 2019/11/17 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/05/22 00:00 [pmc-release]
AID - 10.1038/s41598-020-65479-y [pii]
AID - 65479 [pii]
AID - 10.1038/s41598-020-65479-y [doi]
PST - epublish
SO  - Sci Rep. 2020 May 22;10(1):8575. doi: 10.1038/s41598-020-65479-y.